참고문헌 (23)

1. [1] Azoulay L Filion KB Platt RW Association between incretin-based drugs and the risk of acute pancreatitis . JAMA Intern Med 2016 ; 176 : 1464 – 73 . 27479930 

2. [2] Eurich DT Simpson S Senthilselvan A Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study . BMJ 2013 ; 346 : f2267 . 23618722 

3. [3] Ghatak SB Patel DS Shanker N Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus . Curr Diabetes Rev 2010 ; 6 : 410 – 21 . 20879969 

4. [4] Li L Shen J Bala MM Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies . BMJ 2014 ; 348 : g2366 . 24736555 

5. [5] Cohen D Reports of pancreatitis are 20–30 times more likely with GLP-1 drugs, analysis finds . BMJ 2013 ; 346 : f2607 . 23613543 

6. [6] Kahn SE Incretin therapy and islet pathology: a time for caution . Diabetes 2013 ; 62 : 2178 – 80 . 23596147 

   상세보기

7. [7] Garg R Chen W Pendergrass M Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis . Diabetes Care 2010 ; 33 : 2349 – 54 . 20682680 

   상세보기

8. [8] Giorda CB Picariello R Nada E Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study . Lancet Diabetes Endocrinol 2014 ; 2 : 111 – 5 . 24622714 

   상세보기

9. [9] Hollander PL Li J Frederich R Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus . Diabetes Vascular Dis Res 2011 ; 8 : 125 – 35 . 

10. [10] Green JB Bethel MA Armstrong PW Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes . N Engl J Med 2015 ; 373 : 232 – 42 . 26052984 

    상세보기

11. [11] Raschi E Piccinni C Poluzzi E The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database . Acta Diabetol 2013 ; 50 : 569 – 77 . 22008948 

    상세보기

12. [12] Singh S Chang HY Richards TM Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study . JAMA Intern Med 2013 ; 173 : 534 – 9 . 23440284 

    상세보기

13. [13] Faillie JL Babai S Crepin S Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database . Acta Diabetol 2014 ; 51 : 491 – 7 . 24352344 

    상세보기

14. [14] Rehman MB Tudrej BV Soustre J Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials . Diabetes Metab 2017 ; 43 : 48 – 58 . 27745828 

15. [15] Begg CB Mazumdar M Operating characteristics of a rank correlation test for publication bias . Biometrics 1994 ; 50 : 1088 – 101 . 7786990 

    상세보기

16. [16] Barnett AH Charbonnel B Li J Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy . Clin Drug Investig 2013 ; 33 : 707 – 17 . 

17. [17] White WB Cannon CP Heller SR Alogliptin after acute coronary syndrome in patients with type 2 diabetes . N Engl J Med 2013 ; 369 : 1327 – 35 . 23992602 

    상세보기

18. [18] Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus . N Engl J Med 2013 ; 369 : 1317 – 26 . 23992601 

    상세보기

19. [19] Chou HC Chen WW Hsiao FY Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study . Drug Safety 2014 ; 37 : 521 – 8 . 24859164 

    상세보기

20. [20] American Diabetes Association . Standards of medical care in diabetes—2014 . Diabetes Care 2014 ; 37 (suppl 1) : S14 – 80 . 24357209 

21. [21] Chang CH Lin JW Chen ST Dipeptidyl peptidase-4 inhibitor use is not associated with acute pancreatitis in high-risk type 2 diabetic patients: a nationwide cohort study . Medicine 2016 ; 95 : e2603 . 26886601 

22. [22] Meier JJ Nauck MA Risk of pancreatitis in patients treated with incretin-based therapies . Diabetologia 2014 ; 57 : 1320 – 4 . 24723174 

    상세보기

23. [23] Shihab HM Akande T Armstrong K Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and metaanalysis of randomized trials . World J Metaanal 2015 ; 3 : 254 .